---
title: "Incyte Corp. Stock Underperforms Friday When Compared To Competitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286616241.md"
description: "Incyte Corp. (INCY) shares fell 2.38% to $95.31 on Friday, marking the fourth consecutive day of losses. The stock is 15.12% below its 52-week high of $112.29. In comparison, competitors like Alnylam Pharmaceuticals, Bio-Techne, and BioMarin also experienced declines. The overall market was down, with the S&P 500 and Dow Jones falling 1.24% and 1.07%, respectively."
datetime: "2026-05-15T21:06:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286616241.md)
  - [en](https://longbridge.com/en/news/286616241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286616241.md)
---

# Incyte Corp. Stock Underperforms Friday When Compared To Competitors

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Incyte Corp. (INCY) slipped 2.38% to $95.31 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 1.24% to 7,408.50 and Dow Jones Industrial Average falling 1.07% to 49,526.17.

This was the stock's fourth consecutive day of losses.

Incyte Corp. closed 15.12% short of its 52-week high of $112.29, which the company reached on January 7th.

The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Alnylam Pharmaceuticals Inc. (ALNY) fell 2.20% to $286.98, Bio-Techne Corp. (TECH) fell 3.22% to $43.30, and BioMarin Pharmaceutical Inc. (BMRN) fell 2.69% to $51.81.

Trading volume (1.6 M) eclipsed its 50-day average volume of 1.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled May 15, 2026.

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-15-26 1706ET

### Related Stocks

- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)
- [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [TECH.US](https://longbridge.com/en/quote/TECH.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [FDS.US](https://longbridge.com/en/quote/FDS.US.md)

## Related News & Research

- [Incyte Stock: Analyst Estimates & Ratings](https://longbridge.com/en/news/286932283.md)
- [Incyte And Genesis Expand Molecular Ai Collaboration To Accelerate Drug Discovery](https://longbridge.com/en/news/287067847.md)
- [Incyte CEO Says Post-Jakafi Growth Path Is Clearer as Pipeline Catalysts Build](https://longbridge.com/en/news/286716316.md)
- [A Look At Beam Therapeutics (BEAM) Valuation As New BEACON Trial Data And Partnerships Draw Attention](https://longbridge.com/en/news/286662919.md)
- [Alaunos Reports Preclinical Aln1003 Data Showing Effects On Insulin-Resistance-Related Biomarkers And Liver Histology In Diet-Induced Obesity Models](https://longbridge.com/en/news/286776760.md)